Sandoz Slashes Glatiramer Price In US
Glatopa Brand Around A Quarter Of Copaxone List Price
Executive Summary
Sandoz has cut its US wholesale price for its Glatopa glatiramer acetate brand by more than 70% to offer a substantial difference to both Teva’s Copaxone reference brand and Mylan’s generic.
You may also be interested in...
Teva Sues FDA For Excluding Copaxone From BLA Transition
Teva and US FDA disagree over whether Copaxone is a protein. While generics are already on the market, Teva wants to assert process patents against future would-be competitors, which the firm cannot do through the ANDA pathway.
Teva Sues FDA For Excluding Copaxone From BLA Transition; Wants To Use Biosimilar Litigation Process
Teva and US FDA disagree over whether Copaxone is a protein. While generics are already on the market, Teva wants to assert process patents against future would-be competitors, which the firm cannot do through the ANDA pathway.
Teva On Track To Hit Targets With Truxima
Teva says it is on track to achieve both its sales targets and its restructuring goals as it prepares to enjoy the benefits of being first to market with a rituximab biosimilar in the US.